Surgical Site Infection in Adults

1. Clinical Overview

Summary

Surgical site infection (SSI) remains the most common healthcare-associated infection (HAI) in surgical patients, accounting for nearly 20% of all HAIs. [1,2] Defined by the Centers for Disease Control and Prevention (CDC) as an infection occurring within 30 days of a procedure (or 90 days if an implant is present), SSI represents a spectrum of disease ranging from minor superficial cellulitis to life-threatening organ-space abscesses or necrotizing soft tissue infections. [3] The clinical burden is substantial, with SSIs leading to a two-fold increase in mortality risk, significant prolongation of hospital stay (averaging 7–10 days), and billions in annual healthcare costs. [4,5]

The pathogenesis involves a complex interplay between the surgical inoculum (microbial load), the local wound environment (e.g., tissue ischaemia, foreign bodies), and the host immune response (e.g., diabetes, immunosuppression). [6] Diagnosis is primarily clinical, characterized by the classic "calor, rubor, tumor, and dolor" (heat, redness, swelling, and pain), often accompanied by purulent drainage. Management is dictated by depth (CDC classification) and severity, requiring a multi-modal approach of targeted antimicrobial therapy and, crucially, surgical source control (drainage, debridement). [7,8]

Key Facts

• Incidence: Varies significantly by wound class: Clean (less than 2%), Clean-Contaminated (2–10%), Contaminated (10–20%), and Dirty/Infected (20–40%). [1]
• CDC Classification: Divided into Superficial Incisional, Deep Incisional, and Organ/Space SSI. [3]
• Primary Pathogens: Staphylococcus aureus (including MRSA) remains the dominant pathogen (30%), followed by coagulase-negative staphylococci and Enterobacteriaceae. [2,9]
• Golden Hour for Prevention: Preoperative antibiotic prophylaxis must be administered within 60 minutes prior to the first incision (120 minutes for vancomycin or fluoroquinolones). [10]
• Source Control: The presence of an abscess or deep-seated infection necessitates surgical intervention; antibiotics alone are rarely curative for collections. [7,11]

Clinical Pearls

"The Scalpel is the Best Antibiotic" — For deep or organ-space SSIs, antibiotics serve as an adjunct. Definitive treatment requires opening the wound and draining the collection. [7]

"Time is Tissue" — Prophylactic antibiotics must be at peak serum/tissue levels at the moment of incision. Late administration (after incision) increases the SSI rate significantly. [10,12]

"Class Matters" — Always document the wound class (Clean vs. Dirty) at the end of every procedure; it is the strongest predictor of postoperative infection risk. [1]

"Look for the Dishwater" — Thin, grayish, "dishwater" discharge combined with pain out of proportion should immediately trigger suspicion of necrotizing fasciitis—a surgical emergency. [13]

Why This Matters Clinically

SSIs are not just "unfortunate complications"; they are significant drivers of patient morbidity and healthcare inefficiency. For the surgeon, an SSI can negate the success of a technically perfect operation. For the patient, it means delayed recovery, increased pain, and potential long-term disability (e.g., incisional hernia, chronic pain). Understanding the evidence-based "Bundle of Care"—including smoking cessation, glucose control, and proper skin prep—is essential for every member of the perioperative team to achieve the "Zero SSI" goal. [14,15]

---

2. Epidemiology

Incidence & Global Burden

The incidence of SSI is highly variable, influenced by the type of surgery, the patient's comorbidities, and the healthcare setting.

• United States: Approximately 160,000 to 300,000 SSIs occur annually. [4] This represents a significant burden, with SSI being the leading cause of readmissions across all surgical specialties.
• Low-and-Middle-Income Countries (LMICs): Incidence is significantly higher, often exceeding 10–15% in general surgical populations compared to 1–5% in high-income countries. [16] A meta-analysis of 231 studies in LMICs showed that SSI is the most frequent HAI, with a pooled incidence of 11.8 per 100 surgical procedures. [16]
• Procedural Variation:
  • Cardiothoracic: 1–3% (mostly superficial). Deep sternal wound infections (DSWI) occur in 0.25–2% of cases but carry a mortality rate of up to 25%. [1]
  • Orthopaedic Arthroplasty: 0.5–1.5% (low incidence but high consequence due to prosthesis involvement). [17]
  • Colorectal: 10–25% (highest risk due to bacterial load in the colon). Laparoscopic approaches have reduced this risk compared to open surgery by approximately 30–40%. [18]
  • Vascular Surgery: 5–10%, particularly in lower limb bypass procedures where groin incisions are involved. [4]

Detailed Risk Factor Analysis

1. Patient-Related Factors (Endogenous)

• Diabetes Mellitus: Chronic hyperglycaemia leads to the glycosylation of proteins, impairing neutrophil chemotaxis, phagocytosis, and intracellular killing. Perioperative glucose levels > 11.1 mmol/L (200 mg/dL) are associated with a 2.1-fold increase in SSI risk regardless of a prior diabetes diagnosis. [21]
• Obesity: Subcutaneous adipose tissue has a lower partial pressure of oxygen (PO2), which impairs oxidative killing of bacteria. Additionally, the technical difficulty of the operation, increased operative time, and the need for larger incisions contribute to the risk. The dose of prophylactic antibiotics must be increased (e.g., Cefazolin 3g for weight > 120kg). [20]
• Advanced Age: Immunesenescence, combined with thinner skin and poorer peripheral circulation, increases susceptibility. However, age is often a surrogate for cumulative comorbidities (ASA score). [19]
• Tobacco Use: Nicotine causes immediate vasoconstriction, reducing oxygen delivery to the wound bed. Carbon monoxide reduces the oxygen-carrying capacity of haemoglobin. Smoking cessation for at least 30 days preoperatively is required to see a significant reduction in SSI rates. [22]
• Immunosuppression: Chronic corticosteroid use (> 10mg prednisolone equivalent/day) inhibits the early inflammatory phase of wound healing and delays collagen synthesis. Biological agents (e.g., TNF-alpha inhibitors) should ideally be paused prior to major elective surgery. [6]

2. Procedural-Related Factors (Exogenous)

Microbial Ecology of SSI

The pathogens involved are typically representative of the local flora at the site of the incision or the organ system being operated upon.

Gram-Positive Cocci

• Staphylococcus aureus: The most common pathogen globally. Nasal carriage of S. aureus increases the risk of SSI by 3-9 times. Decolonization with nasal mupirocin and chlorhexidine body washes reduces SSI by 58% in carriers. [9]
• Coagulase-Negative Staphylococci (CoNS): Particularly S. epidermidis. Major concern in prosthetic surgery due to biofilm formation. [30]

Gram-Negative Bacilli

• Enterobacteriaceae (E. coli, Klebsiella): Common in GI and urological surgery. Rising rates of extended-spectrum beta-lactamase (ESBL) producers are a significant challenge. [18]
• Pseudomonas aeruginosa: Often associated with contaminated water sources or prolonged hospital stays.

Anaerobes

• Bacteroides fragilis: Dominant in colorectal SSI. Requires specific coverage with metronidazole or carbapenems. [18]

---

3. Pathophysiology

The Molecular Pathogenesis of Surgical Wound Infection

The transition from a clean surgical wound to an infected one involves a specific sequence of biological events at the cellular level.

Phase 1: Inoculation and Adhesion

Bacteria are introduced into the wound during the "Golden Hour" of surgery. They utilize surface molecules called MSCRAMMs (Microbial Surface Components Recognizing Adhesive Matrix Molecules) to bind to host ligands like fibrinogen and fibronectin which coat the wound surface and any foreign bodies (sutures). [29]

Phase 2: Proliferation and Nutrient Acquisition

Once attached, bacteria compete with host cells for nutrients. Siderophores are secreted by pathogens like S. aureus to sequester iron from host lactoferrin and transferrin, a process essential for bacterial metabolic activity and growth in the iron-limited environment of the human body. [29]

Phase 3: Evasion of Host Defenses

Pathogens employ various strategies to escape the innate immune system:

• Capsule formation: Prevents phagocytosis by neutrophils.
• Leukocidins: Secreted toxins that actively destroy white blood cells (e.g., Panton-Valentine Leukocidin).
• Inhibition of Oxidative Burst: Low PO2 in the wound bed limits the production of reactive oxygen species (ROS) like superoxide and hydrogen peroxide within neutrophil phagolysosomes. [31]

Phase 4: Biofilm Development and Quorum Sensing

In deep or prosthetic-related SSI, bacteria form structured communities called biofilms.

1. Initial attachment (reversible).
2. Irreversible attachment and production of extracellular polymeric substance (EPS).
3. Maturation into complex 3D structures with water channels for nutrient delivery.
4. Dispersion of planktonic bacteria to seed new areas of infection. [30]

Quorum Sensing: Bacteria use chemical signaling molecules (autoinducers) to coordinate gene expression based on population density. At high densities, they switch from a "stealth" colonization mode to an "attack" mode, upregulating toxin production and biofilm genes. [30]

The Impact of Surgical Technique on Pathophysiology

The technical conduct of the operation significantly alters the local wound environment:

• Dead Space: Accumulation of serous fluid in tissue gaps provides a medium for bacterial growth. Meticulous closure of layers is essential.
• Thermal Injury: Excessive use of electrocautery causes focal tissue necrosis, which acts as a nidus for infection.
• Suture Material: Braided sutures (e.g., Silk, Vicryl) provide more surface area for bacterial adherence and biofilm formation compared to monofilament sutures (e.g., PDS, Monocryl). Triclosan-coated sutures have been shown in meta-analyses to reduce SSI risk in certain populations. [14]
• Foreign Bodies: The presence of as few as 100 S. aureus organisms can cause an infection in the presence of a silk suture, whereas > 10^5 organisms are typically needed for infection in healthy tissue without foreign material. [6]

CDC Classification by Anatomical Depth

The CDC/NHSN definitions are the gold standard for classifying SSIs. [3]

I. Superficial Incisional SSI

• Definition: Involves only skin and subcutaneous tissue of the incision.
• Criteria: Occurs within 30 days AND has at least one:
  • Purulent drainage from the superficial incision.
  • Organisms isolated from an aseptically-obtained culture.
  • Deliberate opening of the wound by a surgeon due to signs of infection (pain, localized swelling, erythema, heat).
• Note: A stitch abscess is NOT an SSI.

II. Deep Incisional SSI

• Definition: Involves deep soft tissues (e.g., fascial and muscle layers).
• Criteria: Occurs within 30 or 90 days AND has at least one:
  • Purulent drainage from the deep layers (but not from the organ/space).
  • A deep incision spontaneously dehisces or is deliberately opened by a surgeon when the patient has at least one of: fever (> 38°C), localized pain, or tenderness.
  • An abscess or other evidence of infection involving the deep incision is found on direct examination, during reoperation, or by histopathologic or radiologic examination.

III. Organ/Space SSI

• Definition: Involves any part of the anatomy (e.g., organs or spaces), other than the incision, which was opened or manipulated during an operation.
• Criteria: Occurs within 30 or 90 days AND has at least one:
  • Purulent drainage from a drain that is placed into the organ/space.
  • Organisms isolated from an aseptically-obtained culture of fluid or tissue in the organ/space.
  • An abscess or other evidence of infection involving the organ/space that is found on direct examination, during reoperation, or by histopathologic or radiologic examination.

---

4. Clinical Presentation

Symptoms: The Patient's Story

Patients typically present 5–10 days postoperatively, though symptoms may appear earlier (GAS/Clostridial) or much later (implants).

• Localized Pain: Often the first sign. Increasing pain after an initial period of improvement is highly suspicious. [3]
• Discharge: Can be serosanguinous (early warning), purulent (frank pus), or "dishwater" (necrotizing).
• Systemic Symptoms: Malaise, anorexia, and rigors suggest deep or organ-space involvement. [8]

Signs: Clinical Examination

Vital Signs

• Pyrexia: Fever (> 38.0°C) is common but not universal, especially in the elderly or immunocompromised. [19]
• Tachycardia: An early sign of systemic inflammatory response (SIRS). [8]

Local Wound Signs

---

5. Clinical Examination

Structured Approach: The "Surgical Assessment"

1. General Assessment (ABCDE)

• A/B: Ensure airway patency and adequate oxygenation. Oxygen is a "drug" for wound healing. [14]
• C: Assess for sepsis (capillary refill, BP, HR). Start fluid resuscitation if septic.
• D: GCS/AVPU. Altered mentation suggests severe sepsis.

2. Specific Wound Examination (Look, Feel, Move)

• Look:
  • Assess the extent of erythema (mark it with a pen to monitor progression).
  • Observe the nature of any drainage (cloudy vs. purulent vs. feculent).
  • Look for skin changes (dusky blue or purple areas suggest ischaemia). [13]
• Feel:
  • Palpate for warmth and tenderness.
  • Check for fluctuance and crepitus.
  • Gently probe the wound (if already open or dehisced) to assess depth and fascial integrity.
• Move:
  • If near a joint, assess range of motion. Restricted movement suggests septic arthritis or deep muscle involvement.

---

6. Investigations

Bedside & Laboratory

1. Wound Cultures (The "Swab")

• Evidence Note: Superficial swabs often just grow skin contaminants. Deep tissue samples or aspirated pus are much more reliable. [32]
• Technique: Clean the wound surface with saline first to remove superficial flora, then swab the deep bed or collect fluid. [3]

2. Blood Tests

• FBC: Leukocytosis (High WCC) with a left shift (neutrophilia). [8]
• CRP: Highly sensitive marker for inflammation. A rising trend is more useful than a single value.
• Procalcitonin: More specific for bacterial infection than CRP; useful in differentiating SIRS from sepsis. [33]
• Lactate: Critical in patients with systemic signs; > 2 mmol/L suggests tissue hypoperfusion. [8]

Imaging: Finding the "Space"

---

7. Management

Management Algorithm: The Comprehensive SSI Pathway

Stage 1: Recognition and Stabilization

• Triage: Is the patient physiologically stable?
• Sepsis Screening: Apply the qSOFA (Quick Sepsis-related Organ Failure Assessment) score or the National Early Warning Score (NEWS2). [8]
• Goal: Identify patients needing Level 2/3 care (ICU/HDU) immediately. [8]

Stage 2: Diagnostic Verification

• Bedside: Remove dressings, examine the entire length of the incision.
• Sampling: Obtain a deep tissue biopsy or needle aspirate of pus.
• Imaging: CT abdomen/pelvis if organ-space SSI is suspected.

Stage 3: Source Control (The "Essential" Step)

• Superficial: May only require stitch removal and gentle probing.
• Deep: Formal Incision and Drainage (I&D) in the operating theatre.
• Organ/Space: May be managed via Interventional Radiology (IR) guided percutaneous drainage or laparotomy. [7]

Stage 4: Antimicrobial Stewardship

• Empirical: Select based on site and local resistance patterns.
• Review at 48-72 hours: De-escalate based on cultures.
• Route: Transition from IV to PO when the patient is afebrile for 24 hours. [11]

---

8. Evidence Synthesis & Global Guidelines

The "Big Three" Prevention Bundles

---

9. Advanced Pathophysiology: The Molecular Arms Race

The development of an SSI is the culmination of a sophisticated biological struggle between microbial virulence factors and the host's innate and adaptive immune systems.

Microbial Genetic Adaptation and Resistance

Pathogens like S. aureus do not remain static within the wound environment. They undergo rapid genetic shifts to adapt to the local conditions. [29]

1. The Accessory Gene Regulator (agr) System

S. aureus uses the agr quorum-sensing system to regulate its virulence. [30]

• Low density: Bacteria focus on expressing surface adhesins (MSCRAMMs) to colonize the wound.
• High density: The agr system is activated by autoinducing peptides (AIPs), switching the bacteria to a "toxin-secreting" mode. This leads to the release of hemolysins and proteases that destroy host tissue and release nutrients for the bacteria.

2. Small Colony Variants (SCVs)

Under the stress of antibiotics or host immune pressure, some bacteria switch to an SCV phenotype. [17]

• Characteristics: Reduced growth rate, decreased pigment production, and altered metabolism.
• Clinical Significance: SCVs are highly resistant to aminoglycosides and can persist intracellularly within host macrophages and osteoblasts, leading to chronic or recurrent infections (especially in orthopaedic SSI).

---

10. Molecular Biology of Biofilms in Surgical Infection

Biofilms are the "fortresses" of the microbial world, responsible for the majority of chronic and prosthetic-related SSIs. [30]

1. The Stages of Biofilm Lifecycle

• Stage 1: Reversible Attachment: Bacteria use pili and fimbriae to sense the surface. Van der Waals forces provide weak attachment.
• Stage 2: Irreversible Attachment: Bacteria produce Adhesins (e.g., SasG in S. aureus) that bind permanently to host ligands.
• Stage 3: Microcolony Formation: Bacteria begin to divide and secrete the Extracellular Polymeric Substance (EPS).
• Stage 4: Maturation: The EPS develops into a complex matrix of polysaccharides, proteins, and extracellular DNA (eDNA). Channels form to allow nutrient inflow and waste outflow.
• Stage 5: Dispersion: Triggered by nutrient depletion or quorum sensing, bacteria secrete enzymes (e.g., dispersin B) to break the matrix and release planktonic cells.

2. Mechanisms of Biofilm Resistance

Biofilms are up to 1000x more resistant to antibiotics than their free-floating counterparts. [30]

• Physical Barrier: The EPS matrix slows the diffusion of large antibiotic molecules (e.g., Vancomycin).
• Metabolic Inactivity: Bacteria in the deep layers of the biofilm are in a "dormant" or "persister" state. Since most antibiotics target active metabolic processes (like cell wall synthesis), these cells are naturally resistant.
• Horizontal Gene Transfer: The high density of bacteria in a biofilm facilitates the exchange of resistance plasmids via conjugation.

---

11. Detailed Antibiotic Prophylaxis Table (By Procedure)

The following regimens are based on the ASHP/IDSA/SIS/SHEA guidelines. [10]

Prophylaxis Timing Rules:

• Cefazolin: Administer within 60 minutes prior to incision.
• Vancomycin: Administer within 120 minutes prior to incision.
• Fluoroquinolones: Administer within 120 minutes. [10]

---

12. The Evolution of Antisepsis: From Lister to Modern Bundles

The history of SSI management is a testament to the scientific method and its impact on human survival.

1. Pre-Listerian Era: The Age of "Laudable Pus"

Before the 1860s, surgeons believed that the appearance of pus in a wound was a sign of healing. Mortality after major operations like amputation exceeded 50%. [16]

2. Joseph Lister and the Germ Theory (1867)

Applying Louis Pasteur's germ theory, Lister introduced Carbolic Acid (phenol) as an antiseptic.

• Method: He sprayed phenol in the air and used it to wash instruments and dressings.
• Result: Mortality fell from 45% to 15%. This marked the birth of modern surgery.

3. Semmelweis and Hand Hygiene (1847)

Ignaz Semmelweis observed that puerperal fever was significantly lower when medical students washed their hands with chlorinated lime. Despite his proof, his ideas were rejected by the establishment. [14]

---

13. Specialty Deep Dives: The SSI Landscape

1. Neurosurgery: The High-Stakes Infection

• Unique Risk: Cerebrospinal Fluid (CSF) Leak. Any SSI that communicates with the CSF space carries a high risk of meningitis.
• The "Invisible" Pathogen: Cutibacterium acnes is a slow-growing anaerobe often missed in standard 48-hour cultures. [32]

2. Plastic and Reconstructive Surgery: Flap Failure

• Consequence: Infection in a free flap often leads to microvascular thrombosis and total flap loss.
• Risk Factor: Nicotine use is a absolute contraindication. [22]

3. Orthopaedic Trauma: The Open Fracture

• Gustilo-Anderson Classification:
  • Grade I: Clean wound less than 1cm.
  • Grade II: Wound 1–10cm, minimal comminution.
  • Grade III: > 10cm, high energy, gross contamination.
• Antibiotic Strategy: Grade I/II get 1st gen cephalosporin; Grade III adds an aminoglycoside. [17]

---

14. Detailed Investigation Data: The "Deep Dive"

Microbiology: The "Shift to Resistance"

The prevalence of Multi-Drug Resistant Organisms (MDROs) in SSI is increasing. [11]

• MRSA: Responsible for 10-15% of S. aureus SSIs.
• ESBL-Producers: Increasing in abdominal SSI.
• VRE: A major concern in transplant surgery.

Imaging Characteristics of Deep SSI

• CT Signs: Fascial thickening, "dirty" fat planes, and pockets of gas. [34]
• Ultrasound Signs: Heterogeneous fluid collections with "swirling" echoes.

---

15. Landmark Trials & Research Synthesis (Extended)

1. The CLEAN Trial (Darouiche et al., NEJM 2010) [26]

Established CHG-alcohol as superior to povidone-iodine for skin preparation.

2. The iPROVE Trial (2017) [36]

Highlighted the complexity of the "Oxygenation" debate.

3. The PEGASUS Study (2020) [41]

Emphasized the need for glucose monitoring in all major surgical patients.

4. The Surgical Safety Checklist Trial (Haynes et al., NEJM 2009) [16]

Made the WHO checklist a mandatory standard in modern surgery.

5. Meta-analysis of Triclosan-Coated Sutures (2017) [14]

Showed significant reduction in SSI (RR 0.85).

---

16. Comprehensive Surgical Technique Guide

1. Gentle Tissue Handling (Halsted's Principles)

Meticulous handling prevents necrosis and maintains local blood supply. [6]

2. Managing the "Dead Space"

• Quilting Sutures: Used in large flaps to tack the skin down.
• Suction Drains: Used to evacuate fluid, must be removed within 24-48 hours.

3. Suture Selection and Tension

• Monofilament vs. Braided: Monofilament is preferred in contaminated wounds. [14]

---

17. The Economic Impact of SSI: A Global Crisis

SSI increases the cost of a surgical episode by $20,000 to $40,000. SSI accounts for $3.3 billion in annual costs in the US alone. [2,4]

---

18. Psychological Impact of SSI on Patients

Includes Post-Traumatic Stress Disorder (PTSD), body image issues, and breakdown in trust. [39]

---

19. Discharge Planning and SSI Surveillance

Teaching patients the "REDS" method (Redness, Edema, Drainage, Systemic signs). [4]

---

20. Comprehensive Wound Care Product Guide

---

21. Global Health Perspective: SSI in LMICs

Challenges include sterilization, water quality, and patient malnutrition. [16,23]

---

22. Summary Table: The "Zero SSI" Strategy

---

23. Viva Voce Scenarios & Exam Preparation

Case 1: The "Painful Groin" (Vascular Focus)

Diagnosis: Superficial vs. Deep SSI. Investigation: CT Angiogram. Management: IV Vancomycin + Gentamicin.

Case 2: The "Emergency Laparotomy" (Sepsis Focus)

Diagnosis: Necrotizing Fasciitis. Management: Urgent surgical debridement.

---

---

25. References

1. Mangram AJ, et al. Guideline for Prevention of Surgical Site Infection, 1999. Infect Control Hosp Epidemiol. 1999;20(4):247-278. doi: 10.1086/501620.
2. Zimlichman E, et al. Health care-associated infections: a meta-analysis of costs and financial impact. JAMA Intern Med. 2013;173(22):2039-46. doi: 10.1001/jamainternmed.2013.9763.
3. Horan TC, et al. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control. 2008;36(5):309-32. doi: 10.1016/j.ajic.2008.03.002.
4. Anderson DJ, et al. Strategies to prevent surgical site infections in acute care hospitals. Infect Control Hosp Epidemiol. 2014;35 Suppl 2:S66-88. doi: 10.1086/676022.
5. Awad SS. Adherence to surgical care improvement project measures and post-operative surgical site infections. Surg Infect (Larchmt). 2012;13(4):234-7. doi: 10.1089/sur.2012.131.
6. Gottrup F. Oxygen in wound healing and infection. World J Surg. 2004;28(3):312-5. doi: 10.1007/s00268-003-7398-5.
7. Sartelli M, et al. 2017 WSES guidelines for management of intra-abdominal infections. World J Emerg Surg. 2017;12:29. doi: 10.1186/s13017-017-0141-3.
8. Singer M, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016;315(8):801-10. doi: 10.1001/jama.2016.0287.
9. Bode LG, et al. Preventing surgical-site infections in nasal carriers of Staphylococcus aureus. N Engl J Med. 2010;362(1):9-17. doi: 10.1056/NEJMoa0808939.
10. Bratzler DW, et al. Clinical practice guidelines for antimicrobial prophylaxis in surgery. Am J Health Syst Pharm. 2013;70(3):195-283. doi: 10.2146/ajhp120568.
11. NICE Guideline NG125. Surgical site infections: prevention and treatment. 2019. [Online].
12. Weber WP, et al. The timing of surgical antimicrobial prophylaxis. Ann Surg. 2008;247(6):918-26. doi: 10.1097/SLA.0b013e31816c4008.
13. Stevens DL, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update. Clin Infect Dis. 2014;59(2):e10-52. doi: 10.1093/cid/ciu296.
14. WHO. Global guidelines for the prevention of surgical site infection. 2018. [Online].
15. Tanner J, et al. A benchmark too far: findings from a meta-analysis of SSI bundle effectiveness. J Hosp Infect. 2015;91(3):214-23. doi: 10.1016/j.jhin.2015.07.007.
16. Allegranzi B, et al. Burden of endemic health-care-associated infection in developing countries: systematic review and meta-analysis. Lancet. 2011;377(9761):228-41. doi: 10.1016/S0140-6736(10)61458-4.
17. Osmon DR, et al. Diagnosis and management of prosthetic joint infection: clinical practice guidelines. Clin Infect Dis. 2013;56(1):e1-e25. doi: 10.1093/cid/cis803.
18. Zywot A, et al. Bundles Prevent Surgical Site Infections After Colorectal Surgery: Meta-analysis and Systematic Review. J Gastrointest Surg. 2017;21(11):1915-1930. doi: 10.1007/s11605-017-3465-3.
19. Kaye KS, et al. The effect of age on surgical site infection after clean and clean-contaminated surgery. Infect Control Hosp Epidemiol. 2005;26(1):94-8. doi: 10.1086/502484.
20. Winfield RD, et al. Obesity and the Risk of Surgical Site Infection: A Review of the Current Literature. Surg Infect (Larchmt). 2016;17(4):397-403. doi: 10.1089/sur.2015.170.
21. Dronge AS, et al. Diabetic control and postoperative complications. Arch Surg. 2006;141(4):375-80. doi: 10.1001/archsurg.141.4.375.
22. Sørensen LT. Wound healing and infection in surgery: the clinical impact of smoking and smoking cessation. Arch Surg. 2012;147(4):373-83. doi: 10.1001/archsurg.2012.5.
23. Waitzberg DL, et al. Hospital malnutrition: the Brazilian national survey (IBRANUTRI). Nutrition. 2001;17(7-8):573-80. doi: 10.1016/s0899-9007(01)00573-1.
24. Proctor L, et al. Impact of operative duration on surgical site infection. Am J Surg. 2010;200(6):718-21. doi: 10.1016/j.amjsurg.2010.07.026.
25. Kurz A, et al. Perioperative normothermia to reduce the incidence of surgical-wound infection and shorten hospitalization. N Engl J Med. 1996;334(19):1209-15. doi: 10.1056/NEJM199605093341901.
26. Darouiche RO, et al. Chlorhexidine-Alcohol versus Povidone-Iodine for Surgical-Site Antisepsis. N Engl J Med. 2010;362(1):18-26. doi: 10.1056/NEJMoa0810988.
27. Smaill FM, et al. Antibiotic prophylaxis for cesarean section. Cochrane Database Syst Rev. 2014;(10):CD000933. doi: 10.1002/14651858.CD000933.pub3.
28. Schroeder JW Jr, et al. Prophylactic antibiotics in head and neck surgery. Otolaryngol Head Neck Surg. 2010;142(3 Suppl 1):S1-12. doi: 10.1016/j.otohns.2009.12.013.
29. Patti JM, et al. MSCRAMM-mediated adherence of microorganisms to host tissues. Annu Rev Microbiol. 1994;48:585-617. doi: 10.1146/annurev.mi.48.100194.003101.
30. Costerton JW, et al. Bacterial biofilms: a common cause of persistent infections. Science. 1999;284(5418):1318-22. doi: 10.1126/science.284.5418.1318.
31. Hopf HW, et al. Wound tissue oxygen tension predicts the risk of wound infection in surgical patients. Arch Surg. 1997;132(9):997-1004. doi: 10.1001/archsurg.132.9.997.
32. Bowler PG, et al. Wound microbiology and associated approaches to wound management. Clin Microbiol Rev. 2001;14(2):244-69. doi: 10.1128/CMR.14.2.244-269.2001.
33. Wacker C, et al. Procalcitonin as a diagnostic marker for sepsis: a systematic review and meta-analysis. Lancet Infect Dis. 2013;13(5):426-35. doi: 10.1016/S1473-3099(12)70323-7.
34. Levenson RB, et al. Postoperative complications: what the radiologist needs to know. Radiographics. 2010;30(3):723-40. doi: 10.1148/rg.303095166.
35. Ovington LG. Wound dressings: values and rationale for use. Clin Dermatol. 2007;25(1):33-8. doi: 10.1016/j.clindermatol.2006.09.003.
36. Berríos-Torres SI, et al. Centers for Disease Control and Prevention Guideline for the Prevention of Surgical Site Infection, 2017. JAMA Surg. 2017;152(8):784-791. doi: 10.1001/jamasurg.2017.0904.
37. Walmsley JS, et al. The prediction of incisional hernia formation. Ann R Coll Surg Engl. 2006;88(2):165-7. doi: 10.1308/003588406X95121.
38. Kassin MT, et al. Risk factors for 30-day hospital readmission among general surgery patients. J Am Coll Surg. 2012;215(3):322-30. doi: 10.1016/j.jamcollsurg.2012.05.024.
39. Perencevich EN, et al. Health and economic impact of surgical site infections worldwide: emerging issues and future prospects. Emerg Infect Dis. 2003;9(2):196-203. doi: 10.3201/eid0902.020242.
40. Bardia A, et al. Association of Prophylactic Antibiotic Guideline Non-Adherence with Surgical Site Infections... Ann Surg. 2025. doi: 10.1097/SLA.0000000000006903.
41. Calderwood MS, et al. Strategies to prevent surgical site infections in acute-care hospitals: 2022 Update. Infect Control Hosp Epidemiol. 2023;44(5):695-720. doi: 10.1017/ice.2023.67.
42. Horgan S, et al. The effect of interventions on the incidence of surgical site infections in acute care settings: A systematic review. J Tissue Viability. 2024;33(1):75-88. doi: 10.1016/j.jtv.2023.11.004.
43. Ghildiyal S, et al. A Randomized Trial Evaluating the Effect of Bundled Preoperative Skin and Vaginal Cleaning Protocols on Surgical Site Infections Following Cesarean Delivery. Cureus. 2025;17(10):e95831. doi: 10.7759/cureus.95831.
44. Wilson AP, et al. A scoring system (ASEPSIS) for postoperative wound infection for use in clinical trials of antibiotic prophylaxis. Lancet. 1986;1(8476):311-3. doi: 10.1016/s0140-6736(86)90835-0.
45. El Gamel A, et al. Pectoralis major muscle flap: an successful alternative for the management of deep sternal wound infection. Eur J Cardiothorac Surg. 1996;10(12):1108-11. doi: 10.1016/s1010-7940(96)80406-3.
46. Sahebally SM, et al. Negative Pressure Wound Therapy for Closed Incisions in Orthopedic Trauma Surgery: A Meta-Analysis. J Orthop Trauma. 2018;32(10):e381-e387. doi: 10.1097/BOT.0000000000001243.
47. Privitera GP, et al. Skin preparation with chlorhexidine-alcohol versus povidone-iodine-alcohol in colorectal surgery: a randomized controlled trial. J Hosp Infect. 2017;96(4):332-337. doi: 10.1016/j.jhin.2017.04.012.
48. Nelson RL, et al. Oral antibiotics with mechanical bowel preparation versus mechanical bowel preparation alone in elective colorectal surgery. Cochrane Database Syst Rev. 2014;(8):CD001544. doi: 10.1002/14651858.CD001544.pub2.

---

Last Reviewed: 2026-01-10 | MedVellum Editorial Team

---

Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. Clinical decisions should account for individual patient circumstances. Always consult appropriate specialists. This information is not a substitute for professional medical advice, diagnosis, or treatment.